Abstract
A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have